Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vor Biopharma Inc (VOR)

Vor Biopharma Inc (VOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,393
  • Shares Outstanding, K 68,260
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,863 K
  • 60-Month Beta -0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade VOR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $-0.41 on 08/08/24
  • Next Earnings Date 11/05/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 394.46% ( +120.43%)
  • Historical Volatility 84.43%
  • IV Percentile 88%
  • IV Rank 40.87%
  • IV High 886.54% on 08/15/24
  • IV Low 54.29% on 05/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 107
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 4,577
  • Open Int (30-Day) 3,994

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.40
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.43
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +18.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8200 +13.93%
on 09/03/24
1.1900 -21.50%
on 09/10/24
-0.0168 (-1.77%)
since 08/16/24
3-Month
0.7000 +33.46%
on 08/05/24
1.2700 -26.44%
on 06/26/24
-0.2658 (-22.15%)
since 06/18/24
52-Week
0.7000 +33.46%
on 08/05/24
3.1399 -70.25%
on 01/12/24
-1.2758 (-57.73%)
since 09/18/23

Most Recent Stories

More News
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 19.42 (-0.92%)
PRTC.LN : 143.800 (+0.84%)
BIIB : 197.59 (-0.31%)
KRTX : 329.83 (+0.03%)
VOR : 0.9342 (-2.48%)
AKLI : 0.4320 (-0.62%)
PureTech Provides End of Year Report on Key Progress

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today...

PRTC : 19.42 (-0.92%)
PRTC.LN : 143.800 (+0.84%)
KRTX : 329.83 (+0.03%)
GLS : 0.1586 (+0.38%)
VOR : 0.9342 (-2.48%)
AKLI : 0.4320 (-0.62%)
BIIB : 197.59 (-0.31%)
PureTech Health plc – Half-Year Report

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its half-yearly results for the six months ended June 30, 2022. The following information will be filed...

PRTC : 19.42 (-0.92%)
PRTC.LN : 143.800 (+0.84%)
AKLI : 0.4320 (-0.62%)
GLS : 0.1586 (+0.38%)
DNAA : 14.07 (+47.02%)
RBLX : 45.28 (-1.01%)
CPSR : 7.36 (+9.85%)
KRTX : 329.83 (+0.03%)
VOR : 0.9342 (-2.48%)
Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...

VOR : 0.9342 (-2.48%)
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for...

VOR : 0.9342 (-2.48%)
Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...

VOR : 0.9342 (-2.48%)
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant...

VOR : 0.9342 (-2.48%)
Vor Bio Announces Retirement of Chief Medical Officer

CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that...

VOR : 0.9342 (-2.48%)
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced an agreement...

VOR : 0.9342 (-2.48%)
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022New program VCAR33ALLO using healthy donor-derived T cells IND...

VOR : 0.9342 (-2.48%)

Business Summary

Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.0815
2nd Resistance Point 1.0407
1st Resistance Point 0.9875
Last Price 0.9342
1st Support Level 0.8935
2nd Support Level 0.8527
3rd Support Level 0.7995

See More

52-Week High 3.1399
Fibonacci 61.8% 2.2079
Fibonacci 50% 1.9200
Fibonacci 38.2% 1.6320
Last Price 0.9342
52-Week Low 0.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar